» Articles » PMID: 33968052

Chimerism, the Microenvironment and Control of Leukemia

Overview
Journal Front Immunol
Date 2021 May 10
PMID 33968052
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Transplantation of allogeneic hematopoietic cells faces two barriers: failure of engraftment due to a host versus graft reaction, and the attack of donor cells against the patient, the graft versus host (GVH) reaction. This reaction may lead to GVH disease (GVHD), but in patients transplanted due to leukemia or other malignant disorders, this may also convey the benefit of a graft versus leukemia (GVL) effect. The interplay of transplant conditioning with donor and host cells and the environment in the patient is complex. The microbiome, particularly in the intestinal tract, profoundly affects these interactions, directly and via soluble mediators, which also reach other host organs. The microenvironment is further altered by the modifying effect of malignant cells on marrow niches, favoring the propagation of the malignant cells. The development of stable mixed donor/host chimerism has the potential of GVHD prevention without necessarily increasing the risk of relapse. There has been remarkable progress with novel conditioning regimens and selective T-cell manipulation aimed at securing engraftment while preventing GVHD without ablating the GVL effect. Interventions to alter the microenvironment and change the composition of the microbiome and its metabolic products may modify graft/host interactions, thereby further reducing GVHD, while enhancing the GVL effect. The result should be improved transplant outcome.

Citing Articles

Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.

Azhar Ud Din M, Lin Y, Lyu C, Yi C, Fang A, Mao F Mol Med. 2025; 31(1):2.

PMID: 39754054 PMC: 11699782. DOI: 10.1186/s10020-024-01060-x.


Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis.

Stadler M, Venturini L, Bunting I, Dammann E, Weissinger E, Schwarzer A Front Oncol. 2022; 12:867356.

PMID: 36059667 PMC: 9428843. DOI: 10.3389/fonc.2022.867356.


Consequence of Histoincompatibility beyond GvH-Reaction in Cytomegalovirus Disease Associated with Allogeneic Hematopoietic Cell Transplantation: Change of Paradigm.

Reddehase M, Holtappels R, Lemmermann N Viruses. 2021; 13(8).

PMID: 34452395 PMC: 8402734. DOI: 10.3390/v13081530.

References
1.
Kernan N, Flomenberg N, DuPont B, OReilly R . Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987; 43(6):842-7. View

2.
Bejar R . Implications of molecular genetic diversity in myelodysplastic syndromes. Curr Opin Hematol. 2016; 24(2):73-78. PMC: 5433846. DOI: 10.1097/MOH.0000000000000313. View

3.
Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M . Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019; 3(15):2424-2435. PMC: 6693000. DOI: 10.1182/bloodadvances.2019000143. View

4.
Martin P, Fan W, Storer B, Levine D, Zhao L, Warren E . Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood. 2016; 128(20):2450-2456. PMC: 5114491. DOI: 10.1182/blood-2016-07-728063. View

5.
Jenq R, Taur Y, Devlin S, Ponce D, Goldberg J, Ahr K . Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015; 21(8):1373-83. PMC: 4516127. DOI: 10.1016/j.bbmt.2015.04.016. View